IL6 and head and neck squamous cell carcinoma: In HNSCC, the IL-6/JAK/STAT pathway has been shown to be a potent inducer of EMT, increasing resistance against therapies such as Cetuximab or RT and enhancing metastatic potential [21,22,23].